Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
{{output}}
We present a patient with metastatic NSCLC harboring a compound EGFR mutation with co-occurring G719A and T790M mutation. T790M mutation was treatment emergent mutation when patient was on early generation tyrosine kinase inhibitors. Initial Guardant 360 showe... ...
